Table 1. WHO Approved Antibacterial Repurposed Drugs Included in Treatment Regimen for Drug-Resistant TB.
| S. no. | Drug name and class | Group | Mechanism of action/drug target | Critical concentration | Patient daily dosage | Refs |
|---|---|---|---|---|---|---|
| 1 | Linezolid (Oxazolidinone) | Group-A | 23S rRNA of the 50S subunit | 1 mg/L using LJ medium | 600 mg | (48,49) |
| 2 | Moxifloxacin (Fluoroquinolone) | Group-A | DNA-Gyrase | 1 mg/L using LJ medium | 400 mg | (48,49) |
| 3 | Levofloxacin (Fluoroquinolone) | Group-A | DNA-Gyrase | 2 mg/L using LJ medium | 1 g | (48,49) |
| 4 | Clofazimine (Riminophenazine derivative) | Group-B | Antimicrobial activity is membrane-directed | 1 mg/L using MGIT-DST | 100 mg | (48,49) |
| 5 | Meropenem (β-Lactams) | Group-C | Inhibit cell wall synthesis | NA | 2 g with Clavulanic acid (125 mg) | (48,49) |